A Gloomy Outlook On Macro Trends From Industry CEOs

Nov 01 2023

• By Jessica Merrill

Listen to this article

Pfizer CEO Albert Bourla, Eli Lilly CEO David Ricks and Seagen CEO David Epstein discussed pressing issues facing the pharmaceutical industry at the recent Galien Forum.

Galien Foundation 2023 — Industry CEOs at the Galien Forum • Source: Alaric DeArment

Global tensions and US drug pricing pressure are growing risks to the pharmaceutical sector that could have long-lasting implications, according to some of the industry’s top CEOs, who participated in a panel discussion at the Galien Forum in New York City on 26 October. Pfizer Inc. CEO Albert Bourla, Eli Lilly and Company CEO David Ricks and Seagen Inc. CEO David Epstein discussed pressing issues for the pharmaceutical industry in the post-COVID era.

A new war in the Middle East, coming on top of the ongoing war between Ukraine and Russia, and mounting...

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership
Dec 05 2025
• By Jung Won Shin
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart
Jun 14 2025
• By Nabil
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.